Skip to main content

Table 1 Characteristics of the participants

From: Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study

Baseline characteristics

COPEP population (n = 105)

PLWH (routine TDM) (n = 119)

Median (range) or Number (%)

Median (range) or Number (%)

Demographic characteristics

 Sex (no.):

  Male

45 (43)

50 (42)

  Female

60 (57)

69 (58)

 Age (year)

39 (17—67)

41 (19—78)

 Body weight (kg)

73 (47—157)

66 (40—147)

 Height (cm)

172 (149—192)

168 (148—190)

 BMI (kg/m2)

24 (17—49)

24 (16—51)

Drug and sampling

 Lopinavir dosing (mg):

  200

-

9 (8)

  300

-

1 (1)

  400

105 (100)

85 (71)

  500

-

5 (4)

  600

-

7 (6)

  800

-

10 (8)

  1000

-

2 (2)

 Number of samples per patient

1 (1—1)

2 (1—8)

 Time after dose (h)

1.5 (0.07—19)

10.25 (1.25—29.5)

  1. PLWH People living with HIV, TDM Therapeutic drug monitoring, BMI Body mass index